Dragan Cicic - 07 Jan 2026 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Reporting relationship: SVP, Chief Development Officer
Issuer ticker: SLS
Reported as of: 07 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2026, 16:35:34 UTC
Prior SEC filing: 05 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Daniel Bagliebter, Power of Attorney For: Dragan Cicic

Key filing fact

Dragan Cicic filed Form 4 for SELLAS Life Sciences Group, Inc. (SLS) on 09 Jan 2026.

Key facts

This page summarizes Dragan Cicic's Form 4 filing for SELLAS Life Sciences Group, Inc. (SLS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Jan 2026, 16:35.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001565795 Primary reporting owner

CICIC DRAGAN

Relationship: SVP, Chief Development Officer
Address: C/O SELLAS LIFE SCIENCES GROUP, INC.,, 7 TIMES SQUARE, SUITE 2503, NEW YORK
Signature: /s/ Daniel Bagliebter, Power of Attorney For: Dragan Cicic
Signature date: 09 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLS transaction

Common Stock

Award

Transaction value: $0
Shares: +300,000
Change %: +116%
Price: $0.000000
Shares after: 557,805
Date: 07 Jan 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.